A new pancreatic cancer drug called daraxonrasib cut the risk of death by 60% in a Phase 3 trial. What it is, how it works, ...

In a Phase III trial, Revolution Medicines' daraxonrasib almost doubled the survival length of people with advanced ...

The following day, research supported by another company, Actuate Therapeutics, was published in Nature Medicine showing that ...

A pancreatic cancer drug is showing promising signs of a possible breakthrough after a clinical trial found it nearly doubled ...

A new drug developed at Northwestern University doubled one-year survival in a pancreatic cancer clinical trial.

Former Sen. Ben Sasse gives a glimpse of what it's like to be a participant in an tough but promising new drug for pancreatic ...

Pancreatic cancer research tackles treatment resistance with targeted drug delivery, immune-boosting combinations, and ...

Pancreatic cancer is one of the deadliest cancers and among the hardest to treat, with most patients surviving less than a ...

In the intent-to-treat population, the median OS was 13.2 months with daraxonrasib vs 6.7 months for chemotherapy, ...

A homegrown Northwestern drug is giving Chicago-area families something they almost never get with metastatic pancreatic ...

While you might not know his name, many will recognize his voice. Mark Robertson, local radio icon, has been diagnosed with ...

In a difficult disease, Revolution Medicines achieved what the pancreatic cancer community has long desired: a significant improvement in survival. The Phase 3 results will support global regulatory ...